VirginiaHB4832026 Regular SessionHouse

Prescription Drug Affordability Board; established.

Sponsored By: Karrie K. Delaney (Democratic)

Passed

Summary

Prescription Drug Affordability Advisory Panel established; maximum fair price; annual reports; civil penalties. Directs the Secretary of Health and Human Resources to establish the Prescription Drug Affordability Advisory Panel to conduct data analyses, develop policy recommendations, and identify implementation barriers related to strategies to improve prescription drug affordability, enhance price transparency, and strengthen data collection practices for prescription drugs across public and private payers. The bill requires the Panel to (i) report annually on prescription drug pricing trends and any policy recommendations on legislation to improve prescription drug affordability and (ii) provide quarterly updates on prescription drug pricing trends. The bill requires each pharmacy benefits manager to provide to the Panel, upon request, certain information relating to the dispensation of a referenced drug, as defined in the bill.The bill prohibits prescription drug manufacturers or wholesale distributors permitted or licensed in the Commonwealth from accepting payment at an amount higher than the maximum fair price established by the U.S. Secretary of Health and Human Services pursuant to federal law for the sale of a referenced drug intended for use by individuals in the Commonwealth. Under the bill, an entity that violates such prohibition is subject to a civil penalty of $10,000 per violation. The bill also prohibits a manufacturer subject to its provisions from removing a referenced drug from sale distribution in the Commonwealth for the purpose of avoiding the impact of the bill's rate limitations without providing certain prior notice. Under the bill, a manufacturer that violates such prohibition on removing a referenced drug without the required notice is subject to a civil penalty equal to the greater of $100,000 or the total amount of annual savings for the referenced drug, as determined by the Board of Pharmacy. This bill is identical to SB 271.

Your PRIA Score

Score Hidden

Personalized for You

How does this bill affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & Cosponsors

Sponsor

  • Karrie K. Delaney

    Democratic • House

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

All Roll Calls

Yes: 283 • No: 75

House vote 3/12/2026

Senate substitute agreed to by House

Yes: 87 • No: 11

Senate vote 3/11/2026

Passed Senate with substitute

Yes: 34 • No: 6

Senate vote 3/11/2026

Finance and Appropriations Substitute agreed to

Yes: 0 • No: 0

Senate vote 3/11/2026

Commerce and Labor Substitute rejected

Yes: 0 • No: 0

Senate vote 3/10/2026

Constitutional reading dispensed Block Vote (on 2nd reading)

Yes: 37 • No: 0

Senate vote 3/10/2026

Passed by for the day Block Vote (Voice Vote)

Yes: 0 • No: 0

Senate vote 3/9/2026

Reported from Finance and Appropriations with substitute

Yes: 10 • No: 4

Senate vote 3/9/2026

Reported from Commerce and Labor with substitute and rereferred to Finance and Appropriations

Yes: 12 • No: 3

House vote 2/13/2026

Read third time and passed House

Yes: 61 • No: 33

House vote 2/9/2026

Reported from Appropriations

Yes: 17 • No: 5

House vote 2/6/2026

Subcommittee recommends reporting

Yes: 6 • No: 1

House vote 1/29/2026

Reported from Labor and Commerce with amendment(s) and referred to Appropriations

Yes: 14 • No: 8

House vote 1/27/2026

Subcommittee recommends reporting with amendment(s) and referring to Appropriations

Yes: 5 • No: 4

Actions Timeline

  1. Passed by for the day

    4/23/2026House
  2. Passed by for the day

    4/22/2026House
  3. Governor's Action Deadline 11:59 p.m., May 23, 2026

    4/22/2026Governor
  4. Communicated to Governor

    4/22/2026House
  5. Governor's recommendation received by House

    4/13/2026Governor
  6. Fiscal Impact Statement from Department of Planning and Budget (HB483)

    3/31/2026House
  7. Governor's Action Deadline 11:59 p.m., April 13, 2026

    3/31/2026Governor
  8. Enrolled Bill communicated to Governor on March 31, 2026

    3/31/2026House
  9. Signed by Speaker

    3/31/2026House
  10. Bill text as passed House and Senate (HB483ER)

    3/30/2026House
  11. Enrolled

    3/30/2026House
  12. Signed by President

    3/30/2026Senate
  13. Fiscal Impact Statement from Department of Planning and Budget (HB483)

    3/23/2026House
  14. Senate substitute agreed to by House (87-Y 11-N 0-A)

    3/12/2026House
  15. Passed Senate with substitute (34-Y 6-N 0-A)

    3/11/2026Senate
  16. Finance and Appropriations Substitute agreed to

    3/11/2026Senate
  17. Commerce and Labor Substitute rejected

    3/11/2026Senate
  18. Engrossed by Senate - committee substitute

    3/11/2026Senate
  19. Read third time

    3/11/2026Senate
  20. Passed by for the day Block Vote (Voice Vote)

    3/10/2026Senate
  21. Constitutional reading dispensed Block Vote (on 2nd reading) (37-Y 0-N 0-A)

    3/10/2026Senate
  22. Committee substitute printed 26109533D-S2

    3/10/2026Senate
  23. Rules suspended

    3/10/2026Senate
  24. Committee substitute printed 26109394D-S1

    3/9/2026Senate
  25. Senate committee offered

    3/9/2026Senate

Bill Text

Related Bills

Back to State Legislation